{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T05:05:35Z","timestamp":1788584735571,"version":"build-2803163510"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"SI","license":[{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Investigator-Initiated Studies Program of Merck Sharp & Dohme","award":["Bayer AG"],"award-info":[{"award-number":["Bayer AG"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>In SSc, angiogenesis impairment advances in parallel with the development of fibrosis orchestrated by myofibroblasts originating from different sources, including endothelial-to-mesenchymal transition (EndoMT). Soluble guanylate cyclase (sGC) stimulation has shown antifibrotic effects in SSc skin fibroblasts and mouse models. Here, we investigated the effects of pharmacological sGC stimulation on impaired angiogenesis and myofibroblast-like features of SSc dermal microvascular endothelial cells (SSc-MVECs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>To determine whether sGC stimulation affected cell viability\/proliferation, SSc-MVECs and healthy dermal MVECs (H-MVECs) were challenged with the sGC stimulator (sGCS) MK-2947 and assayed by annexin V\/propidium iodide flow cytometry and the water-soluble tetrazolium salt (WST-1) assay. To study angiogenesis and EndoMT, MK-2947-treated SSc-MVECs were subjected to wound healing and capillary morphogenesis assays and analysed for the expression of endothelial\/myofibroblast markers and contractile ability.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>MK-2947 treatment did not affect H-MVEC viability\/proliferation, while it significantly increased SSc-MVEC proliferation, wound healing capability and angiogenic performance. After MK-2947 treatment, SSc-MVECs exhibited significantly increased proangiogenic MMP9 and decreased antiangiogenic MMP12 and PTX3 gene expression. A significant increase in the expression of CD31 and vascular endothelial cadherin paralleled by a decrease in \u03b1-smooth muscle actin, S100A4, type I collagen and Snail1 mesenchymal markers was also found in MK-2947-treated SSc-MVECs. Furthermore, stimulation of sGC with MK-2947 significantly counteracted the intrinsic ability of SSc-MVECs to contract collagen gels and reduced phosphorylated-extracellular signal-regulated kinases 1 and 2 protein levels.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>These findings demonstrate for the first time that pharmacological sGC stimulation effectively ameliorates the angiogenic performance and blunts the myofibroblast-like profibrotic phenotype of SSc-MVECs, thus providing new evidence for repurposing sGCSs for SSc.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keac433","type":"journal-article","created":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T13:33:23Z","timestamp":1659015203000},"page":"SI125-SI137","source":"Crossref","is-referenced-by-count":14,"title":["Soluble guanylate cyclase stimulation fosters angiogenesis and blunts myofibroblast-like features of systemic sclerosis endothelial cells"],"prefix":"10.1093","volume":"62","author":[{"given":"Eloisa","family":"Romano","sequence":"first","affiliation":[{"name":"Department of Experimental and Clinical Medicine, Division of Rheumatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Rosa","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, Section of Anatomy and Histology, University of Florence , Florence"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca Saveria","family":"Fioretto","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, Division of Rheumatology"},{"name":"Department of Experimental and Clinical Medicine, Section of Anatomy and Histology, University of Florence , Florence"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilia","family":"Giuggioli","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences for Children and Adults, Scleroderma Unit, University of Modena and Reggio Emilia , Modena"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3956-8480","authenticated-orcid":false,"given":"Mirko","family":"Manetti","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, Section of Anatomy and Histology, University of Florence , Florence"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Matucci-Cerinic","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, Division of Rheumatology"},{"name":"Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Hospital , Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,7,28]]},"reference":[{"key":"2023020607513619700_keac433-B1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.5301\/jsrd.5000249","article-title":"Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities","volume":"2","author":"Varga","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"key":"2023020607513619700_keac433-B2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.trsl.2019.02.010","article-title":"Evolving insights into the cellular and molecular pathogenesis of fibrosis in systemic sclerosis","volume":"209","author":"Korman","year":"2019","journal-title":"Transl Res"},{"key":"2023020607513619700_keac433-B3","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.3390\/jcm9092687","article-title":"The pathogenesis of systemic sclerosis: an understanding based on a common pathologic cascade across multiple organs and additional organ-specific pathologies","volume":"9","author":"Asano","year":"2020","journal-title":"J Clin Med"},{"key":"2023020607513619700_keac433-B4","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1161\/CIRCRESAHA.111.242057","article-title":"Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis","volume":"109","author":"Manetti","year":"2011","journal-title":"Circ Res"},{"key":"2023020607513619700_keac433-B5","doi-asserted-by":"crossref","first-page":"7078","DOI":"10.1111\/jcmm.16727","article-title":"Epigenetic down-regulation of microRNA-126 in scleroderma endothelial cells is associated with impaired responses to VEGF and defective angiogenesis","volume":"25","author":"Wang","year":"2021","journal-title":"J Cell Mol Med"},{"key":"2023020607513619700_keac433-B6","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1136\/annrheumdis-2018-213239","article-title":"Slit2\/Robo4 axis may contribute to endothelial cell dysfunction and angiogenesis disturbance in systemic sclerosis","volume":"77","author":"Romano","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2023020607513619700_keac433-B7","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/annrheumdis-2016-210229","article-title":"Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis","volume":"76","author":"Manetti","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023020607513619700_keac433-B8","first-page":"610","article-title":"New insights into profibrotic myofibroblast formation in systemic sclerosis: when the vascular wall becomes the enemy","volume":"11","author":"Romano","year":"2021","journal-title":"Life (Basel)"},{"key":"2023020607513619700_keac433-B9","doi-asserted-by":"crossref","first-page":"S157","DOI":"10.5152\/eurjrheum.2019.19081","article-title":"The contribution of mesenchymal transitions to the pathogenesis of systemic sclerosis","volume":"7","author":"Rosa","year":"2020","journal-title":"Eur J Rheumatol"},{"key":"2023020607513619700_keac433-B10","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1515\/hsz-2018-0155","article-title":"From molecules to patients: exploring the therapeutic role of soluble guanylate cyclase stimulators","volume":"399","author":"Sandner","year":"2018","journal-title":"Biol Chem"},{"key":"2023020607513619700_keac433-B11","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00210-019-01779-z","article-title":"cGMP: a unique 2nd messenger molecule \u2013 recent developments in cGMP research and development","volume":"393","author":"Friebe","year":"2020","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"2023020607513619700_keac433-B12","doi-asserted-by":"crossref","first-page":"5492","DOI":"10.1038\/s41467-021-25617-0","article-title":"Activation mechanism of human soluble guanylate cyclase by stimulators and activators","volume":"12","author":"Liu","year":"2021","journal-title":"Nat Commun"},{"key":"2023020607513619700_keac433-B13","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.coph.2014.12.014","article-title":"Renal effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence","volume":"21","author":"Stasch","year":"2015","journal-title":"Curr Opin Pharmacol"},{"key":"2023020607513619700_keac433-B14","first-page":"71","article-title":"Nitric oxide-independent activation of soluble guanylate cyclase by BAY 60-2770 in experimental liver fibrosis","volume":"58","author":"Knorr","year":"2008","journal-title":"Arzneimittelforschung"},{"key":"2023020607513619700_keac433-B15","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1053\/j.gastro.2011.12.017","article-title":"Role of differentiation of liver sinusoidal endothelial cells in progression and regression of hepatic fibrosis in rats","volume":"142","author":"Xie","year":"2012","journal-title":"Gastroenterology"},{"key":"2023020607513619700_keac433-B16","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3390\/biomedicines8090330","article-title":"BAY 41-2272 attenuates CTGF expression via sGC\/cGMP-independent pathway in TGF\u03b21-activated hepatic stellate cells","volume":"8","author":"Chen","year":"2020","journal-title":"Biomedicines"},{"key":"2023020607513619700_keac433-B17","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s10157-014-1029-3","article-title":"Deficiency of endothelial nitric oxide signaling pathway exacerbates peritoneal fibrosis in mice","volume":"19","author":"Kadoya","year":"2015","journal-title":"Clin Exp Nephrol"},{"key":"2023020607513619700_keac433-B18","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/hr.2009.64","article-title":"Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressure-overloaded rat heart","volume":"32","author":"Masuyama","year":"2009","journal-title":"Hypertens Res"},{"key":"2023020607513619700_keac433-B19","doi-asserted-by":"crossref","first-page":"1345402","DOI":"10.1155\/2019\/1345402","article-title":"Combined activation of guanylate cyclase and cyclic AMP in lung fibroblasts as a novel therapeutic concept for lung fibrosis","volume":"2019","author":"Lambers","year":"2019","journal-title":"Biomed Res Int"},{"key":"2023020607513619700_keac433-B20","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.yexcr.2015.08.014","article-title":"Activators and stimulators of soluble guanylate cyclase counteract myofibroblast differentiation of prostatic and dermal stromal cells","volume":"338","author":"Zenzmaier","year":"2015","journal-title":"Exp Cell Res"},{"key":"2023020607513619700_keac433-B21","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1136\/annrheumdis-2011-200862","article-title":"Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis","volume":"71","author":"Beyer","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2023020607513619700_keac433-B22","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1136\/annrheumdis-2013-204508","article-title":"Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGF\u03b2 signalling","volume":"74","author":"Beyer","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2023020607513619700_keac433-B23","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1136\/annrheumdis-2014-206809","article-title":"Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies","volume":"74","author":"Dees","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2023020607513619700_keac433-B24","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13075-021-02513-y","article-title":"Soluble guanylate cyclase stimulator reduced the gastrointestinal fibrosis in bleomycin-induced mouse model of systemic sclerosis","volume":"23","author":"Yamamoto","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2023020607513619700_keac433-B25","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"2023020607513619700_keac433-B26","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s13075-019-1979-7","article-title":"A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers","volume":"21","author":"Nagaraja","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2023020607513619700_keac433-B27","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/cpt.10","article-title":"Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension","volume":"97","author":"Dasgupta","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"2023020607513619700_keac433-B28","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1097\/HJH.0b013e32833b558c","article-title":"Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models","volume":"28","author":"Sharkovska","year":"2010","journal-title":"J Hypertens"},{"key":"2023020607513619700_keac433-B29","doi-asserted-by":"crossref","first-page":"e43433","DOI":"10.1371\/journal.pone.0043433","article-title":"The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats","volume":"7","author":"Lang","year":"2012","journal-title":"PLoS One"},{"key":"2023020607513619700_keac433-B30","doi-asserted-by":"crossref","first-page":"9372","DOI":"10.1038\/s41598-018-27656-y","article-title":"The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats","volume":"8","author":"Schwabl","year":"2018","journal-title":"Sci Rep"},{"key":"2023020607513619700_keac433-B31","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"Riociguat for the treatment of pulmonary arterial hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N Engl J Med"},{"key":"2023020607513619700_keac433-B32","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/annrheumdis-2015-209087","article-title":"Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2","volume":"76","author":"Humbert","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023020607513619700_keac433-B33","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1183\/09031936.00182909","article-title":"Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study","volume":"36","author":"Ghofrani","year":"2010","journal-title":"Eur Respir J"},{"key":"2023020607513619700_keac433-B34","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1136\/annrheumdis-2019-216823","article-title":"Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial","volume":"79","author":"Khanna","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2023020607513619700_keac433-B35","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2023020607513619700_keac433-B36","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s13075-016-1122-y","article-title":"Bosentan and macitentan prevent the endothelial-to-mesenchymal transition (EndoMT) in systemic sclerosis: in vitro study","volume":"18","author":"Corallo","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2023020607513619700_keac433-B37","doi-asserted-by":"crossref","first-page":"e12440","DOI":"10.1111\/micc.12440","article-title":"Microvascular involvement in systemic sclerosis and systemic lupus erythematosus","volume":"26","author":"Saygin","year":"2019","journal-title":"Microcirculation"},{"key":"2023020607513619700_keac433-B38","first-page":"133","article-title":"A new avenue in the pathogenesis of systemic sclerosis: the molecular interface between the endothelial and the nervous systems","volume":"37","author":"Romano","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"2023020607513619700_keac433-B39","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1124\/jpet.106.108878","article-title":"Soluble guanylyl cyclase activation promotes angiogenesis","volume":"319","author":"Pyriochou","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"2023020607513619700_keac433-B40","doi-asserted-by":"crossref","first-page":"R824","DOI":"10.1152\/ajpregu.00222.2009","article-title":"The soluble guanylyl cyclase inhibitor NS-2028 reduces vascular endothelial growth factor-induced angiogenesis and permeability","volume":"298","author":"Morbidelli","year":"2010","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"2023020607513619700_keac433-B41","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ijcard.2019.07.017","article-title":"Protective role of endothelial progenitor cells stimulated by riociguat in chronic thromboembolic pulmonary hypertension","volume":"299","author":"Yamamoto","year":"2020","journal-title":"Int J Cardiol"},{"key":"2023020607513619700_keac433-B42","doi-asserted-by":"crossref","first-page":"e15156","DOI":"10.14814\/phy2.15156","article-title":"Modulation of soluble guanylate cyclase ameliorates pulmonary hypertension in a rat model of chronic thromboembolic pulmonary hypertension by stimulating angiogenesis","volume":"10","author":"Zagorski","year":"2022","journal-title":"Physiol Rep"},{"key":"2023020607513619700_keac433-B43","first-page":"A15850","article-title":"Stimulation of soluble guanylate cyclase activity with riociguat promotes angiogenesis and improves neovascularization after hindlimb ischemia [abstract]","volume":"134","author":"Dhahri","year":"2016","journal-title":"Circulation"},{"key":"2023020607513619700_keac433-B44","doi-asserted-by":"crossref","first-page":"9161","DOI":"10.1073\/pnas.1202916109","article-title":"Hydrogen sulfide and nitric oxide are mutually dependent in the regulation of angiogenesis and endothelium-dependent vasorelaxation","volume":"109","author":"Coletta","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"2023020607513619700_keac433-B45","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.atherosclerosis.2020.05.012","article-title":"The NO-donor MPC-1011 stimulates angiogenesis and arteriogenesis and improves hindlimb ischemia via a cGMP-dependent pathway involving VEGF and SDF-1\u03b1","volume":"304","author":"Gomes de Almeida Schirmer","year":"2020","journal-title":"Atherosclerosis"},{"key":"2023020607513619700_keac433-B46","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1124\/jpet.103.050385","article-title":"Nitric oxide and cyclic GMP increase the expression of matrix metalloproteinase-9 in vascular smooth muscle","volume":"307","author":"Marcet-Palacios","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"2023020607513619700_keac433-B47","doi-asserted-by":"crossref","first-page":"16898","DOI":"10.1073\/pnas.0702761104","article-title":"Nitric oxide regulates matrix metalloproteinase-9 activity by guanylyl-cyclase-dependent and -independent pathways","volume":"104","author":"Ridnour","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"2023020607513619700_keac433-B48","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1016\/S2665-9913(20)30356-8","article-title":"The multifaceted problem of pulmonary arterial hypertension in systemic sclerosis","volume":"3","author":"Bruni","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2023020607513619700_keac433-B49","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1016\/j.ajpath.2015.03.019","article-title":"Endothelial to mesenchymal transition contributes to endothelial dysfunction in pulmonary arterial hypertension","volume":"185","author":"Good","year":"2015","journal-title":"Am J Pathol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keac433\/45416350\/keac433.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/SI\/SI125\/49085068\/keac433.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/SI\/SI125\/49085068\/keac433.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T07:52:29Z","timestamp":1675669949000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/62\/SI\/SI125\/6651059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,28]]},"references-count":49,"journal-issue":{"issue":"SI","published-online":{"date-parts":[[2022,7,28]]},"published-print":{"date-parts":[[2023,2,6]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keac433","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,2,1]]},"published":{"date-parts":[[2022,7,28]]}}}